Eliquis: third new oral anticoagulant in CanadaIt is the third new oral anticoagulant to reach the Canadian market, joining rivaroxaban and dabigatran etexilate. Birth control formulation linked to elevated VTE riskYaz, Yasmin contain drospirenone Weight loss leads to lasting benefits in heart function Study involving obese patients points to usefulness of imaging in monitoring results of various treatments Bioresorbable stent shows promise in North American trial Quebec woman recovering well two months after scaffold implanted Xarelto approved for stroke prevention in atrial fibrillation Drug was previously indicated only for the prevention of venous thromboembolic events. Resting heart rate increase linked to higher risk of heart disease death Statins turn off bad clotting Home AFib detection Apixaban less effective than enoxaparin in preventing VTE But problems with study design may have undermined results, researchers note Colchicine reduces postoperative atrial fibrillation But larger trials over longer period needed, lead researcher warns First Previous 69 70 71 72 73 Next Last
